<![CDATA[Risvutatug Rezetecan Improves Overall Survival in Relapsed SCLC Trial]]>
Phase 3positiveRisvutatug RezetecanPositive
AI Analysis
Summary
Risvutatug Rezetecan demonstrated positive overall survival data in the Phase 3 ARTEMIS-008 trial for relapsed SCLC, marking the first B7-H3–targeted antibody-drug conjugate to show such results in any tumor type.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
First Phase 3 trial to show positive overall survival data for a B7-H3–targeted antibody-drug conjugate in any tumor type
Importance:8/10
Sentiment:
0.85
Phase_3_DataOncologySCLCADCOverall_SurvivalARTEMIS-008
Related Companies
Read the original article
Published by Cancer Network on July 12, 2026 4:00 PM